Key Highlights

  • Pfizer (NYSE:PFE) reports third quarter 2026 results before the open on Tuesday, November 3, 2026. Calendar consensus adjusted EPS is USD 0.73, and the Market Value is near USD 173.26 billion.
  • Guidance as of August 2026 calls for Revenue of USD 60.5 billion to USD 62.5 billion. The midpoint was lifted by USD 500 million to USD 61.5 billion, while adjusted EPS of USD 2.80 to USD 3.00 was left unchanged.
  • Second quarter revenue reached USD 15.0 billion against a consensus of USD 14.388 billion. Launched and acquired products brought in USD 3.2 billion, up 18 percent year over year.
  • COVID revenue is expected near USD 4 billion for 2026, down from USD 5 billion, and one published estimate puts third quarter revenue at about USD 15.91 billion.

What the Market Expects

The Earnings calendar shows adjusted EPS of USD 0.73 for Pfizer (NYSE:PFE), and one published estimate puts revenue near USD 15.91 billion, though its source is not identified and it should be treated as unverified. First quarter adjusted EPS was USD 0.75 against USD 0.92 a year earlier, on revenue of USD 14.5 billion. The 2026 adjusted EPS guide of USD 2.80 to USD 3.00 already absorbs an in-process R&D charge of about USD 0.10 per share tied to the Innovent Biologics transaction, which can make quarterly comparisons uneven. Third quarter also faces a tough comparison, because the year-earlier period carried higher COVID revenue alongside strong non-COVID growth, according to published research.

COVID Decline Versus Non-COVID Growth

The core question is whether growth products can outrun shrinking COVID sales. Comirnaty and Paxlovid fell 59 percent and 63 percent in the first quarter, and low COVID incidence could keep limiting Paxlovid use, with Comirnaty sales concentrated toward year end. Offsetting that in part, Padcev, Nurtec, Lorbrena and Vyndaqel are driving non-COVID growth, and Pfizer (NYSE:PFE) has cited an additional USD 2.5 billion of cost savings, for USD 9.7 billion in total through 2029. Guidance also includes about USD 1.5 billion of pressure from generic and biosimilar competition, and the oncology portfolio acquired with Seagen was reported up 21 percent in the second quarter excluding one-time items.

Pipeline, Patents and Scenarios

Vyndamax Patent settlements extend effective U.S. protection to June 1, 2031, so Vyndamax revenue is now expected to stay relatively stable from 2028 to mid-2031. Pipeline catalysts include MEVPRO-1, an amylin and GLP-1 combination and Phase 3 progress for berobenatide in obesity. A bull case is revenue near USD 16 billion with a guidance raise and clear pipeline timelines. A bear case is weaker Paxlovid Demand or Margin pressure from a high comparison base, with management still reiterating its commitment to maintain and grow the Dividend over time. A 5 percent move either way would shift market value by about USD 8.7 billion, simple arithmetic and not options-implied.

Where Things Stand

The company is Pfizer (NYSE:PFE), and the answer to the headline question is that the report should show a Business growing outside COVID but still shrinking in total. Guidance of USD 60.5 billion to USD 62.5 billion in revenue and USD 2.80 to USD 3.00 in adjusted EPS frames expectations. Any change to that guidance will matter more than the quarterly EPS. COVID demand, generic pressure and pipeline updates are the main risks and catalysts for November 3.